|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2003-10-22
|
|
pubmed:abstractText |
More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1538-3598
|
|
pubmed:author |
pubmed-author:AlbainKathy SKS,
pubmed-author:AverbuchSteven DSD,
pubmed-author:BelaniChandra PCP,
pubmed-author:BibbW FWF,
pubmed-author:CellaDavidD,
pubmed-author:HerbstRoy SRS,
pubmed-author:KayAndrea CAC,
pubmed-author:KrisMark GMG,
pubmed-author:LynchThomas JTJJr,
pubmed-author:NataleRonald BRB,
pubmed-author:OchsJudith JJJ,
pubmed-author:PragerDianeD,
pubmed-author:SandlerAlanA,
pubmed-author:SchillerJoan HJH,
pubmed-author:SpiridonidisHarrisH,
pubmed-author:WolfMichael KMK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
22
|
|
pubmed:volume |
290
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2149-58
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:14570950-Administration, Oral,
pubmed-meshheading:14570950-Adult,
pubmed-meshheading:14570950-Aged,
pubmed-meshheading:14570950-Aged, 80 and over,
pubmed-meshheading:14570950-Antineoplastic Agents,
pubmed-meshheading:14570950-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14570950-Double-Blind Method,
pubmed-meshheading:14570950-Enzyme Inhibitors,
pubmed-meshheading:14570950-Female,
pubmed-meshheading:14570950-Humans,
pubmed-meshheading:14570950-Lung Neoplasms,
pubmed-meshheading:14570950-Male,
pubmed-meshheading:14570950-Middle Aged,
pubmed-meshheading:14570950-Quinazolines,
pubmed-meshheading:14570950-Receptor, Epidermal Growth Factor,
pubmed-meshheading:14570950-Survival Analysis,
pubmed-meshheading:14570950-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
|
|
pubmed:affiliation |
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
